Global Osteoporosis Therapeutics Industry

• Publication date: May 2012
• Report size: 455 pages

This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report p...

This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key and niche players such as Abbott Laboratories, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Servier SA, Unigene Laboratories, Inc., and Warner Chilcott plc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Global Therapy Industry

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Bisphosphonates I-4
Hormone Replacement Therapy/Estrogen Replacement Therapy I-4
Estrogens I-4
Estrogens/Progesterones I-4
Calcitonins I-4
Selective Estrogen Receptor Modulators (SERMs) I-4
Other Therapeutics I-5


II. EXECUTIVE SUMMARY

1. OUTLOOK II-1
Generic Incursion Drubs Market Revenues Worldwide II-1
Novel Therapies to Recuperate Market Growth II-2
Denosumab Bodes Significant Market Opportunities II-2

2. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE II-3
Bisphosphonates II-3
The leading Therapeutic Market - Only for Now II-3
ERT Drugs II-3
Ups and Downs in the ERT Market II-3
SERMs (Selective Estrogen Receptor Modulators) II-3
Market Overview II-3
Calcitonins II-4
Market Overview II-4
Monoclonal Antibodies (Denosumab) II-4
Market Overview II-4
New Drugs/Drug Classes in Pipeline II-4
End-Stage Therapies (Under Development) for Osteoporosis
Prevention/Cure II-4
SERMs II-5
Eli Lilly Drops Clinical Study of Arzoxifene for Bone Loss II-6
Pfizer Intends to Withdraw NDAs for Fablyn II-6
Bisphosphonates II-6
Zoledronic Acid II-6
Pamidronate II-6
Calcitonin II-7
Emisphere’s Oral Calcitonin Candidate Fails to Clear
Clinical Trials II-7
Parathyroid Hormone (PTH) II-7
Novartis Terminates Clinical Study of Oral Formulation of
PTH1-34 II-7
Monoclonal Antibodies - Denosumab II-7
Table 1: Comparison of Major Osteoporosis Drugs in Reducing
Risk of Fracture II-8
RANK Ligand II-8
Combination Therapy II-9
Others II-9
Cathepsin K inhibitors II-9
Merck Releases New Data for Odanacatib II-9

3. MARKET DYNAMICS II-10
Facts & Figures: The Osteoporosis Primacy II-10
Snapshots II-10
Table 2: Prevalence of Osteoporosis and Osteopenia in Major
Markets including US, Germany, Italy, France, UK, Spain and
Japan: 2003-2013 (In Millions) (includes corresponding
Graph/Chart) II-10
Osteoporosis Therapeutics: An Evolutionary Scan II-10
Currently Available Drugs for Osteoporosis Treatment II-11
“A Sketch of the Present Industry Scenario” II-11
Factors Influencing Demand II-12
Altering Competitive Landscape in Osteoporosis Market II-12
Table 3: Leading Drugs in the Global Osteoporosis
Therapeutics Market (2006-2009): Value Sales for Actonel,
Fosamax, Evista, Boniva, Forteo and Aclasta/Reclast in US$
Million (includes corresponding Graph/Chart) II-13

Table 4: Leading Osteoporosis Therapies and its Cost per Day II-14
Market Trends and Issues II-14
Poor Disease Detection - A Major Market Constraint II-14
Reluctance to Undergo HRT to Increase Osteoporosis Burden II-14
Patent Expiries to Impact Market Growth II-14
Limitations Bog Down Current Therapies II-15
Growth Opportunities Galore for New Drugs II-15
Bisphosphonates to Lose Market Value II-15
Poor Compliance Mars Use of Bisphosphonates II-16
Side Effects of HRT Fuel Natural Alternatives Sales II-16
Bone Formation Drugs Augur New Prospects II-16
A Sneak Into Various Options in Antiresorptives, Anabolic
Therapeutics II-17
Estrogen Replacement Therapy: Will Dosing Make a Difference? II-18
Is Prevention Always Better Than Cure? II-18
Peptide-Based Osteoporosis Therapy Gaining Ground II-18
Polymorphism- A Potent Diagnostic Marker II-18
Bisphosphonates - The Other Side II-19
Efficacy of Evista under the Scanner II-19

4. PRODUCT OVERVIEW II-20
The “Silent Thief” II-20
An Introduction to Bone Physiology II-20
How Osteoporosis Steps In II-20
Osteoporosis: Major Types II-21
Primary Osteoporosis II-21
Secondary Osteoporosis II-21
Osteoporosis - The Aftermath II-22
Prevention: The Only Better Way Out II-22
Osteoporosis Therapies: A Cursory Glance II-23
Non-drug Therapy II-23
Drug Therapy II-23
Major Osteoporosis Therapeutic Classes: A Brief Review II-23
Bisphosphonates II-23
Classification of Bisphosphonates II-24
Alendronate II-24 Etidronate II-24
Risedronate II-24
Calcitonins: A Relatively Safer Therapeutic II-24
What It Is II-24
What It Does II-25
Major Types II-25
Salmon Calcitonin II-25
SERM: A Breakthrough II-25
Raloxifene: Most Widely Approved SERM II-25
SERMs: The Positive Angle II-26
SERMs: The Negative Side II-26
Hormone Replacement Therapy/Estrogen Replacement Therapy: The
Longstanding Therapeutic II-26
ERT: The Positive Side II-26
The Negative Angle to ERT II-27
Tereparatide: The First Anabolic Agent II-27
Composition II-27
Forteo: A Leading Brand II-27
Major Osteoporosis Therapeutic Classes at a Glance II-27
Osteoporosis Therapeutics: A Peek into the Major Brands II-28

5. PRODUCT INTRODUCTIONS/APPROVALS II-30
Pfizer Launches Bazedoxifene in Japan II-30
Daiichi Files for Approval of Denosumab in Japan II-30
Amgen Obtains FDA Approval for Prolia (denosumab) in Treating
Post-Menopausal Osteoporosis II-30
Amgen Obtains EC Approval for Marketing Prolia® II-31
Teva to Launch Generic Version of Evista II-31
Eli Lilly Obtains FDA Approval for Expanded Indication of Forteo® II-31
WANBURY Introduces a Calcium Brand, CDENSE, in India II-32
Yissum Launches New Compound for Osteoporosis Treatment II-32
Novartis Bags US Approval for Reclast II-32
Wyeth Obtains EC Approval for Conbriza™ II-32
Ono and Astellas Introduce Bonoteo in Japan II-33
European Commission Grants Approval to Pfizer for FABLYN® Tablets II-33

6. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER II-34
MDRNA Receives Tentative Approval for New Osteoporosis Drug II-34
Novartis Receives EU Approval for Aclasta II-34
Sun Pharmaceutical Industries Receives Approval for Fosamax (S) II-34
Dr Reddy's Obtains Approval for Production and Marketing of
Generic Fosamax II-34
Aurobindo Pharma Obtains Approval for Introducing Sodium
Tablets in the US II-34
Procter & Gamble Obtains Approval for Actonel II-35
Eli Lilly Obtains European Commission Approval for FORSTEO® II-35
Ranbaxy Collaborates with Virchow to Introduce Bonista
Teriparatide Injection II-35
Barr Pharmaceuticals Subsidiary Introduces Generic
Osteoporosis Drug II-35
Teva Pharmaceutical Industries Obtains Approval for Generic
Fosamax® Tablets II-35
P&G Receives FDA Approval for New Dosage of Actonel II-36
Takeda Introduces Benet® for Osteoporosis Treatment II-36
Labtec Obtains Approval to Market Hormone Replacement Patch in
Europe II-36
Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA II-36
Merck’s New Dosage of FOSAMAX PLUS D Gains FDA Approval II-37
Japanese Pharma Majors Receive Approval for Generic
Osteoporosis Drug II-37
Roche and GlaxoSmithKline Introduce Bonviva II-37
GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA
Approval II-38
Nycomed’s Preotact Recommended for Approval in Europe II-38
Procter & Gamble and Sanofi-Aventis’ Actonel Approved for Male
Osteoporosis II-38
Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray II-38
Teva Receives Tentative FDA Approval for Risedronate Sodium
Tablets II-39
GlaxoSmithKline and Roche Receive Approval for Bonviva in
Switzerland II-39
Roche’s Once-a-month Bisphosphonate Gets FDA Nod II-39
Actonel with Calcium® Obtains FDA Approval II-40
FDA Approves Unigene’s Nasal Calcitonin II-40

7. MAJOR CLINICAL TRIALS/FINDINGS II-41
Azelon Pharmaceuticals Completes Phase II trails for Comparing
Nasal Spray Formulation of Teriparatide with Forteo,
Administered Subcutaneously II-41
GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics II-41
Radius Initiates Phase II Trials for BA058 II-42
Novartis and Nordic Initiate Phase III Clinical Trial of Oral
Salmon Calcitonin II-42
Medivir Initiates First Human Trials for MIV-701 II-42
Osteologix Begins Phase II Trial of NB S101 II-42
Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C™ II-43
Acceleron Initiates Phase I Clinical Trial of ACE-011 II-43
Positive Results from Reclast Clinical Trials II-44

8. RECENT INDUSTRY ACTIVITY II-45
Sanofi Amends Agreement with Warner Chilcott for Actonel® II-45
Oramed and Laser Detect Systems Ink Joint Venture Agreement II-45
Orchid Chemicals and Pharmaceuticals, and Alvogen Ink Agreement II-45
Abbott Takes Over Solvay Pharmaceuticals II-45
Novartis Obtains Clearance To Continue Clinical Trials on Oral
Calcitonin II-46
Merck Merges with Schering-Plough II-46
Warner Chilcott Acquires Pharmaceuticals Business of P&G II-46
Unigene Laboratories Signs Agreement with Tarsa Therapeutics II-46
Bone Medical Obtains Formal Response from FDA for Capsitonin’s
IND II-47
US District Court Confirms Validity of Eli Lilly’s Patent for
Evista® II-47
US District Court Confirms Validity of Unigene's Patent for
Fortical® II-47
Ajinomoto Announces Japan Rights for Risedronate Hydrate from P&G II-47
Amgen and GSK Join Forces to Market Denosumab II-48
Galapagos-Lily Collaboration Achieves Milestone in
Osteoporosis Treatment II-48
EffRx and Nycomed Sign Licensing Deal for EX101 II-48
Pfizer Takes Over Wyeth II-49
Pfizer Obtains Complete Response Letter from US FDA for
Lasofoxifene II-49
Wockhardt Signs Agreement with DSM Nutritional for Launch of
Bonistein in India II-49

9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-50
MorphoSys and Galapagos Form Long-Term Development Alliance II-50
Daiichi Sankyo Establishes Ireland-Based Subsidiary II-50
Merck and Japan Tobacco Sign Global Licensing Agreement for
JTT-305 II-50
Zelos Therapeutics Signs Agreements for Registration Study of
ZT-031 II-50
NuVasive Takes Over Osteocal Biologics Business of Osiris
Therapeutics II-51
Eli Lilly and TransPharma Medical Sign Licensing and
Development Agreement II-51
Bone Medical Joins Hands with Hyundai Pharm. for Marketing PTH
in South Korea II-52
Eli Lilly to Acquire Osteoporosis Drug Patch from TransPharma
Medical II-52
Wyeth Obtains Approvable Letter from FDA for Bazedoxifene II-52
Daiichi Sankyo Establishes Subsidiary in Turkey II-52
Aegis Therapeutics and Zelos Therapeutics Sign Agreement for
ZT-031 II-52
Teijin Pharma Obtains a License from Dong Wha Pharm for DW-1350 II-53
IOF Signs Agreements with Chinese Organizations for
Osteoporosis Treatment II-53
DAIICHI SANKYO Takes Over EVISTA® from Eli Lilly II-53
Daiichi Sankyo Acquires Developing and Marketing Rights for
Denosumab in Japan II-53
Schering-Plough Acquires Organon BioSciences II-54
Faes Farma Signs Marketing Agreement with Roche and
GlaxoSmithKline II-54
Alethia and Emerillon Collaborate on Osteoporosis Therapies II-54
Ipsen Enters into Co-marketing Agreement with MSD II-55
Unigene Enters into Agreement with Novartis II-55
Pharming Group Granted Subsidies to Develop Osteoporosis Drugs II-55
Procter & Gamble Terminates Nasal Spray Collaboration with
Nastech Pharmaceutical II-56
Pharming Group Acquires DNage II-56
Amgen Acquires Abgenix II-56
P&G Licenses Osteoporosis Nasal Spray Rights from Nastech II-56
Eli Lilly to Close Basingstoke Plant II-57
Galapagos Acquires Drug Discovery Platform of Discovery Partners II-57
Duravest Acquires Bio-Magnetic Therapy II-57
Galapagos Acquires ProStrakan’s ProSkelia II-58
Roche Inks a Marketing Agreement with Elder Pharma II-58
Chugai and Taisho Sign a Joint Development and Marketing
Agreement II-58
Theragenex Signs a Licensing Agreement with Zylera II-59
Radius Acquires Licensing Agreement for Eisai’s SERMs II-59
Alkermes Partners with Eli Lilly to Develop and Market PTH
Formulation II-59
Radius Acquires Exclusive Rights to Karo Bio’s SARMS II-59
Unigene Enters into Agreement with Tzamal Bio II-60
Galapagos Acquires Inpharmatica II-60
Bio-Rad Acquires Provalis Medical Diagnostics Operations II-60
Daiichi Sankyo to Market Evista in Europe II-60
Biocon Acquires Nobex II-61
Radius and Ipsen Enters into Licensing Agreement II-61
Novartis Acquires Hexal AG II-61
Nippon Chemiphar Signs Agreement with Velcura Therapeutics II-62
Biopotential Capital Acquires Osta Biopharma II-62
Dnage Commences DNA Research Programme for Osteoporosis
Therapeutics II-62
Nastech Initiates Phase I Study of PTH 1-34 II-62

10. FOCUS ON SELECT GLOBAL PLAYERS II-63
Eli Lilly and Company (US) II-63
F.Hoffmann-La Roche Ltd (Switzerland) II-63
Merck & Co., Inc. (US) II-63
Novartis AG (Switzerland) II-63
Pfizer, Inc. (US) II-63
Wyeth (US) II-64
Sanofi SA (France) II-64
Servier SA (France) II-65
Unigene Laboratories, Inc. (US) II-65
Warner Chilcott plc (Ireland) II-65

11. GLOBAL MARKET PERSPECTIVE II-66
Table 5: World Recent Past, Current & Future Analysis for
Osteoporosis Therapeutics by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-66

Table 6: World Historic Review for Osteoporosis Therapeutics
by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-67

Table 7: World 15-Year Perspective for Osteoporosis
Therapeutics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe, and Rest of World Markets
for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-68

Table 8: World Recent Past, Current & Future Analysis for
Bisphosphonates by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-69

Table 9: World Historic Review for Bisphosphonates by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-70

Table 10: World 15-Year Perspective for Bisphosphonates by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-71

Table 11: World Recent Past, Current & Future Analysis for ERT
Drugs by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-72

Table 12: World Historic Review for ERT (Estrogen Replacement
Therapy) Drugs by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-73

Table 13: World 15-Year Perspective for ERT (Estrogen
Replacement Therapy)Drugs by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Japan, Europe, and Rest of
World Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) II-74

Table 14: World Recent Past, Current & Future Analysis for
SERMs by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-75

Table 15: World Historic Review for SERMs (Selective Estrogen
Receptors Modulators) by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) II-76

Table 16: World 15-Year Perspective for SERMs (Selective
Estrogen Receptors Modulators) by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Japan, Europe,
and Rest of World Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) II-77

Table 17: World Recent Past, Current & Future Analysis for
Calcitonins by Geographic Region - US, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-78

Table 18: World Historic Review for Calcitonins by Geographic
Region - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-79

Table 19: World 15-Year Perspective for Calcitonins by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-80

Table 20: World Recent Past, Current & Future Analysis for MAB
(Denosumab) by Geographic Region - US, Japan, Europe, and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-81

Table 21: World 15-Year Perspective for MAB (Denosumab) by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-82


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Industry Overview III-1
Osteoporosis in the US: An Insight III-1
Osteoporosis - An Underserved Market? III-1
Statistical Review III-1
Table 22: Osteoporosis Prevalence in Post-Menopause Women
(includes corresponding Graph/Chart) III-2

Table 23: Number of Osteoporosis Patients Undergoing
Osteoporosis Therapies (In Thousands) (includes
corresponding Graph/Chart) III-3
Osteoporosis Prescription Market III-4
Table 24: US Osteoporosis Prescription Market (2004-2006):
Percentage Share of Leading Drugs - Fosamax, Actonel,
Evista, Boniva, Forteo and Others (includes corresponding
Graph/Chart) III-4
Competitive Scenario III-4
Table 25: Leading Players in the US Osteoporosis Market
(2004 - A Historic Review) - Market Share by Value Sales
for Merck, Eli Lilly, Procter & Gamble/ Sanofi, and Others
(includes corresponding Graph/Chart) III-5
Competitive Review by Segment - A Historic Review III-5
Bisphosphonates III-5
Table 26: Leading Players in the US Bisphosphonates Market
(2004) - Market Share by Value Sales for Merck and Procter
& Gamble/ Sanofi (includes corresponding Graph/Chart) III-5
SERMs III-6
Calcitonins III-6
Patent Expiry of Major Osteoporosis Drugs III-6
B.Market Analytics III-7
Table 27: The US Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Group -
Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB
(Denosumab) and Others Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) III-7

Table 28: The US Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, Calcitonins and Others Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-8

Table 29: The US 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs,
Calcitonins, MAB (Denosumab) and Others Markets for Years
2003, 2011 & 2017 (includes corresponding Graph/Chart) III-9

2. JAPAN III-10
Market Analytics III-10
Table 30: Japanese Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB
(Denosumab)Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-10

Table 31: Japanese Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-11

Table 32: Japanese 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs,
Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-12

3. EUROPE III-13
A.Market Analysis III-13
Forteo: The First Anabolic Agent in Europe III-13
European Regulatory Restricts HRT III-13
Calcitonin Embraces New Label III-13
Table 33: European Market for Osteoporosis Therapeutics
(2005- A Historic Review): Market Share of Leading Players-
Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter &
Gamble, Schering, Solvay and Others (includes corresponding
Graph/Chart) III-14
B.Market Analytics III-15
Table 34: European Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Geographic Region-
France, Germany, The UK, Italy, Spain, and Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-15

Table 35: European Historic Review for Osteoporosis
Therapeutics by Geographic Region - France, Germany, The UK,
Italy, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-16

Table 36: European 15-Year Perspective for Osteoporosis
Therapeutics by Geographic Regions - Percentage Breakdown of
Dollar Sales for France, Germany, The UK, Italy, Spain, and
Rest of Europe Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-17

Table 37: European Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB
(Denosumab) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-18

Table 38: European Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-19

Table 39: European 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs,
Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-20

3a. FRANCE III-21
Market Analytics III-21
Table 40: French Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-21

Table 41: French Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-22

Table 42: French 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and
Calcitonins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-23

3b. GERMANY III-24
Market Analytics III-24
Table 43: German Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-24

Table 44: German Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-25

Table 45: German 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and
Calcitonins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-26

3c. ITALY III-27
Market Analytics III-27
Table 46: Italian Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-27

Table 47: Italian Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-28

Table 48: Italian 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and
Calcitonins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-29

3d. THE UNITED KINGDOM III-30
A.Market Analysis III-30
Table 49: Osteoporosis Population in the UK: 2004-2009 III-30
B.Market Analytics III-31
Table 50: The UK Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-31

Table 51: The UK Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-32

Table 52: The UK 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and
Calcitonins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-33

3e. SPAIN III-34
Market Analytics III-34
Table 53: Spanish Recent Past, Current & Future Market
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-34

Table 54: Spanish Historic Review for Osteoporosis
Therapeutics by Product Group - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-35

Table 55: Spanish 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and
Calcitonins Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-36

3f. REST OF EUROPE III-37
A.Market Analysis III-37
Romania III-37
B.Market Analytics III-37
Table 56: Rest of Europe Recent Past, Current & Future
Analysis for Osteoporosis by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-37

Table 57: Rest of Europe Historic Review for Osteoporosis
Therapeutics by Product Groups - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-38

Table 58: Rest of Europe 15-Year Perspective for
Osteoporosis Therapeutics by Product Group - Percentage
Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-39

4. REST OF WORLD III-40
A.Market Analysis III-40
Prevalence of Osteoporosis in Various Region - At a Glance III-40
Korea III-40
Table 59: Korean Osteoporosis Therapeutics Market by
Leading Brands (2005 - A Historic Review): Percentage Share
Breakdown by Dollar Sales for Fosamax, Atonel, Alend,
Maxmarvil, and Others (includes corresponding Graph/Chart) III-40
China III-40
B.Market Analytics III-41
Table 60: Rest of World Recent Past, Current & Future
Analysis for Osteoporosis Therapeutics by Product Groups -
Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB
(Denosumab) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-41

Table 61: Rest of World Historic Review for Osteoporosis
Therapeutics by Product Groups - Bisphosphonates, ERT Drugs,
SERMs, and Calcitonins Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-42

Table 62: Rest of World 15-Year Perspective for Osteoporosis
Therapeutics by Product Group - Percentage Breakdown of
Dollar Sales for Bisphosphonates, ERT Drugs, SERMs,
Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-43


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 49 (including Divisions/Subsidiaries - 63)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 24
Canada 4
Japan 7
Europe 21
France 3
Germany 3
The United Kingdom 3
Italy 2
Spain 1
Rest of Europe 9
Asia-Pacific (Excluding Japan) 5
Middle East 2
------------------------------------------